Sobi Receives Complete Response Letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)
BLA FilingCRLNASPNegative
AI Analysis
Summary
Sobi received a Complete Response Letter from the FDA for its NASP (nanoencapsulated sirolimus plus pegadricase) Biologics License Application, indicating the application was not approved in its current form.
Outcome Details
Complete Response Letter received from FDA for NASP BLA
Importance:8/10
Sentiment:
-0.80
regulatoryFDABLACRLsetback
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on June 26, 2026 2:06 AM